What is it about?
IDH1 mutations have been observed in substantial percentages of various tumor types, such as glioma (80%), acute myeloid leukemia (AML, 20%), cholangiocarcinoma (20%), melanomas (5-10%) and chondrosarcoma (60%). IDH1 mutations lead to reprogramming of metabolism and solid tumors with IDH1 mutations show improved responses to treatment with irradiation or chemotherapy.
Featured Image
Why is it important?
In this study, we describe the mechanism behind the chemosensitivity of the widely-used anti-cancer agent cisplatin in IDH1-mutated cancer cells. We show that the altered stress responses and energy metabolism underlie the sensitivity of IDH1-mutated cancer cells to cisplatin, and that IDH1 mutant inhibitor protects IDH1-mutated cancer cells to cisplatin exposure.
Perspectives
This study improves our understanding of IDH1-mutated malignancy biology, paves the way for clinical research in IDH1-mutated cancer cells and provides key insights for the safe application of IDH1-mutant inhibitors.
Mohammed Khurshed
Universiteit van Amsterdam
Read the Original
This page is a summary of: IDH1-mutant cancer cells are sensitive to cisplatin and an IDH1-mutant inhibitor counteracts this sensitivity, The FASEB Journal, June 2018, Federation of American Societies For Experimental Biology (FASEB),
DOI: 10.1096/fj.201800547r.
You can read the full text:
Contributors
The following have contributed to this page
